MyHep All (Sofosbuvir & Velpatasvir)

MyHep All (Sofosbuvir & Velpatasvir): Uses, Dosage, Benefits & Precautions

Chronic Hepatitis C is a serious viral infection that can silently damage the liver over years if left untreated. Fortunately, modern antiviral therapy has transformed Hepatitis C from a long-term, hard-to-manage illness into a condition that can often be cured within a matter of weeks. MyHep All (Sofosbuvir & Velpatasvir) is one such fixed-dose combination medicine widely used in the management of chronic Hepatitis C virus (HCV) infection.

This article explains what MyHep All is, how it works, its recommended usage, potential side effects, and important precautions to keep in mind.

What is MyHep All (Sofosbuvir & Velpatasvir)?

MyHep All is a fixed-dose combination tablet containing two active ingredients:

• Sofosbuvir 400 mg
• Velpatasvir 100 mg

It is manufactured in India under license and is recognized as a generic version of the branded medicine Epclusa. MyHep All belongs to a class of medicines known as direct-acting antivirals (DAAs), which work by targeting the hepatitis C virus directly rather than relying solely on the body’s immune response.

Why This Combination Matters

The combination of Sofosbuvir and Velpatasvir is significant because it is designed to be effective across all six major HCV genotypes, meaning a single regimen can potentially treat most strains of Hepatitis C, simplifying diagnosis-to-treatment pathways for both doctors and patients.

How Does MyHep All Work?

Each component in MyHep All targets the hepatitis C virus at a different stage of its life cycle:

Sofosbuvir – NS5B Polymerase Inhibitor

Sofosbuvir works by blocking an enzyme called NS5B polymerase, which the hepatitis C virus needs to replicate its genetic material. By inhibiting this enzyme, Sofosbuvir slows down and eventually stops the virus from multiplying.

Velpatasvir – NS5A Inhibitor

Velpatasvir targets a different viral protein called NS5A, which is essential for viral replication and assembly. Blocking NS5A further disrupts the virus’s ability to reproduce and spread within the liver.

Together, these two mechanisms create a dual-action antiviral effect, reducing the viral load in the body and giving the immune system a better chance to clear the infection and allow the liver to begin healing.

Uses of MyHep All

MyHep All is primarily prescribed for:

• Treatment of chronic Hepatitis C virus (HCV) infection in adults
• Use across all major HCV genotypes (genotype 1 through 6)
• Management of HCV infection in patients with or without compensated cirrhosis
• Sometimes used in combination with Ribavirin, depending on the patient’s genotype and liver condition, as decided by the treating physician

Who May Be Prescribed MyHep All?

A doctor may consider MyHep All for adult patients diagnosed with chronic Hepatitis C after reviewing:

• HCV genotype and viral load
• Liver function tests
• Prior treatment history (treatment-naïve or treatment-experienced)
• Presence of liver cirrhosis, if any

Dosage Guidelines

Note: The information below is general and for educational purposes only. Actual dosage must always be determined by a qualified healthcare provider based on individual health status.

• MyHep All is typically taken as one tablet, once daily, with or without food
• The tablet should be swallowed whole and not crushed or split
• The standard treatment duration is around 12 weeks, although this can vary based on the patient’s genotype, liver condition, and treatment history
• Missing doses or stopping treatment early can reduce the medicine’s effectiveness and may contribute to drug resistance

What If a Dose Is Missed?

If a dose is missed and it has been less than 18 hours since the scheduled time, the tablet may still be taken. If more than 18 hours have passed, patients are generally advised to skip the missed dose and continue with the next scheduled dose — but this should always be confirmed with a treating doctor rather than self-adjusted.

Benefits of MyHep All

• Broad genotype coverage – effective across all major HCV genotypes
• Simplified regimen – single tablet, once-daily dosing improves adherence
• High cure rates – direct-acting antivirals like Sofosbuvir and Velpatasvir have significantly improved Hepatitis C treatment outcomes compared to older interferon-based therapies
• Shorter treatment duration – typically a 12-week course compared to older regimens that lasted much longer
• Usable in patients with compensated cirrhosis, under medical supervision

Possible Side Effects

Like all medicines, MyHep All may cause side effects in some patients. Common side effects reported include:

• Headache
• Fatigue or tiredness
• Nausea
• Diarrhea
• Sleep disturbances (insomnia)

When to Contact a Doctor

Patients should seek medical advice promptly if they experience:

• Signs of liver problems, such as yellowing of the skin or eyes, dark urine, or unusual tiredness
• Irregular heartbeat, dizziness, or fainting (especially if also taking heart rhythm medicines like amiodarone)
• Any severe or persistent side effects

Precautions & Safety Information

Before starting MyHep All, patients should inform their doctor if they have:

• A history of Hepatitis B infection (reactivation risk during HCV treatment)
• Kidney disease, including patients on dialysis
• Liver problems other than Hepatitis C
• HIV infection
• Recently used amiodarone or other heart rhythm medications
• Any known allergies to Sofosbuvir, Velpatasvir, or related compounds

Pregnancy and Breastfeeding

MyHep All is generally not recommended for use during pregnancy or breastfeeding unless specifically advised by a physician, especially when the regimen includes Ribavirin, which carries known risks in pregnancy.

Drug Interactions

Sofosbuvir and Velpatasvir can interact with certain other medications, including some heart medicines, acid-reducing drugs, anticonvulsants, and other antiviral drugs. A complete list of current medications should always be shared with the prescribing doctor to avoid interactions.

Storage Instructions

• Store MyHep All tablets at room temperature, away from direct heat and moisture
• Keep the medicine in its original packaging until ready to use
• Keep out of reach of children and pets

Frequently Asked Questions (FAQs)

Is MyHep All a cure for Hepatitis C?

MyHep All, when taken exactly as prescribed for the full recommended duration, has been associated with high cure rates in clinical use of Sofosbuvir/Velpatasvir combinations. However, individual outcomes depend on genotype, liver health, and treatment adherence, and only a doctor can confirm cure status through follow-up testing.

How long does treatment with MyHep All last?

Most patients are prescribed a 12-week course, though the exact duration depends on individual clinical factors as assessed by the treating physician.

Can MyHep All be taken with food?

Yes, MyHep All can generally be taken with or without food, but patients should follow their doctor’s specific instructions.

Is a prescription required for MyHep All?

Yes, MyHep All is a prescription-only medicine and should never be taken without medical supervision.

Conclusion

MyHep All (Sofosbuvir & Velpatasvir) represents an important advancement in the treatment of chronic Hepatitis C, offering broad genotype coverage, a simplified once-daily dosing schedule, and a relatively short treatment course. As with any antiviral medication, successful treatment depends on an accurate diagnosis, proper dosage, and strict adherence to the prescribed regimen under a qualified healthcare provider’s guidance.

Disclaimer:-

This content is intended for general informational and educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. MyHep All (Sofosbuvir & Velpatasvir) is a prescription medicine, and its use should only be undertaken under the supervision of a qualified healthcare professional. Do not start, stop, or change any medication dosage without consulting your doctor. The publisher does not guarantee the accuracy, completeness, or timeliness of the information provided and is not liable for any actions taken based on this content. Always read the product label and package insert, or consult your physician or pharmacist, for complete prescribing information.

References:-

https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

https://my.clevelandclinic.org/health/diseases/15664-hepatitis-c

https://www.cdc.gov/hepatitis-c/about/index.html